SMAD4 and neoplasm: Notably, studies of human cell lines have given inconsistent results of how SMAD4 status influences TGF-β responsiveness and of other tumor biological properties, leading to conflicting conclusions on the impact of SMAD4 defects on PDAC prognosis [18,19].